Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04076813 · ClinicalTrials.gov registry record
Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry
A clinical trial of Myocardial Infarction, sponsored by Chiesi USA.
- Active
- Registry status
- 5,050
- Enrollment target
- 11
- Study locations
NCT04076813: Active study of Myocardial Infarction, sponsored by Chiesi USA.
NCT04076813 is a study of Myocardial Infarction that is active but no longer recruiting, run by Chiesi USA. The registered enrollment target is 5,050 participants, above the 4,603-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (10% higher). The trial reports 11 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04076813, a study of Myocardial Infarction, is active but no longer recruiting, sponsored by Chiesi USA.
- ACTIVE NOT RECRUITING
- Registry status
- 5,050 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this registry is to address optimal platelet inhibition during the early management of MI patients prior to coronary angiography or CABG.
Primary Outcome
Antiplatelet use, including switching and discontinuation will be measured by medical record report. The medical record report will include medication start and stop dates and times.
Conditions Studied
Study Locations (11)
California
- The Regents of the University of California on behalf of its San Diego campus - La Jolla
Delaware
- Christiana Care Health Services, Inc. - Newark
Florida
- University of Florida - Gainesville
Idaho
- Kootenai Hospital District dba Kootenai Health - Coeur d'Alene
Maryland
- MedStar Health Research Institute, Inc. - Hyattsville
Massachusetts
- The Brigham and Women's Hospital, Inc. - Boston
Michigan
- Henry Ford Health System - Detroit
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,050 participants |
| Start Date | 2019-10-16 |
| Est. Completion | 2025-06-30 |
What the registry record for NCT04076813 still lists
NCT04076813 is an observational study that tracks outcomes without assigning an intervention. Its 5,050 participants enrollment target places it among the larger protocols in the corpus, above the 4,603-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (10% higher).
The record links to 1 condition, with Myocardial Infarction appearing as the primary indexed condition, and to 0 interventions.
NCT04076813 lists 11 locations in 11 states (California, Delaware, Florida).
Frequently Asked Questions
What is clinical trial NCT04076813 about?
NCT04076813 is a clinical study titled "Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry". The purpose of this registry is to address optimal platelet inhibition during the early management of MI patients prior to coronary angiography or CABG.
What is the current status of trial NCT04076813?
This trial is currently active not recruiting. The enrollment target is 5,050 participants. The study started on 2019-10-16. Estimated completion is 2025-06-30.
What conditions does trial NCT04076813 study?
This clinical trial studies the following conditions: Myocardial Infarction.
Who is sponsoring clinical trial NCT04076813?
This trial is sponsored by Chiesi USA, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04076813 being conducted?
This trial has 11 study locations across California, Delaware, Florida, Idaho, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Infarction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04076813's enrollment target sits among peer trials
5,050 12th of 64 higher than 53 of 64 other Myocardial Infarction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myocardial Infarction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
Women's Heart Attack Research Program: Stress Ancillary Study
RECRUITING · NA
-
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
RECRUITING
-
Heart Attack Research Program: Platelet Sub-Study (HARP)
RECRUITING
-
Circulating Markers for Ischemic Heart Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07037459 · 5,056 participants · Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- NCT06292078 · 5,076 participants · NA
Preventing School Exclusion and Opioid Misuse: Effectiveness of the Inclusive Skill-building Learning Approach (ISLA)
- NCT04743362 · 5,010 participants
A Study of Noninvasive Methods to Evaluate Skin and Mucosal Conditions
- NCT05018611 · 5,100 participants · NA
Digital Limited Interaction Efficacy Trial of LifeSkills Mobile to Reduce HIV Incidence in YTW
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI